STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANAB
  4. [Form 4] ANAPTYSBIO, INC Insider Trading Activity

AnaptysBio (ANAB) director Rita Jain granted options and 4,000 RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AnaptysBio director Rita Jain reported new equity awards. On January 6, 2026, she received a stock option covering 5,500 shares of AnaptysBio common stock with an exercise price of $43.91 per share. According to the disclosure, this option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, so long as she continues to provide services to the company.

The filing also shows a grant of 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs are scheduled to vest 100% on the date of AnaptysBio’s 2027 annual meeting of shareholders, again conditioned on continued service. After these awards, Jain beneficially owns 5,500 stock options and 4,000 RSUs directly.

Positive

  • None.

Negative

  • None.
Insider Jain Rita
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 5,500 $0.00 --
Grant/Award Restricted Stock Unit 4,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 5,500 shares (Direct); Restricted Stock Unit — 4,000 shares (Direct)
Footnotes (1)
  1. The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jain Rita
(Last) (First) (Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $43.91 01/06/2026 A 5,500 (1) 01/05/2036 Common Stock 5,500 $0 5,500 D
Restricted Stock Unit (2) 01/06/2026 A 4,000 (3) (3) Common Stock 4,000 $0 4,000 D
Explanation of Responses:
1. The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
2. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
3. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Eric Loumeau, Attorney-in-Fact 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in the latest AnaptysBio (ANAB) Form 4 filing?

The insider is Rita Jain, who is reported as a director of AnaptysBio, Inc. with no officer or 10% owner status indicated in the filing.

What stock options did AnaptysBio director Rita Jain receive on January 6, 2026?

On January 6, 2026, Rita Jain was granted a stock option for 5,500 shares of AnaptysBio common stock with an exercise price of $43.91 per share. The option vests as to 1/12 of the total shares monthly beginning on February 6, 2026, subject to her continued service.

How many restricted stock units did Rita Jain receive from AnaptysBio?

The filing shows that Rita Jain received 4,000 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of AnaptysBio common stock upon settlement for no cash consideration.

When do Rita Jain’s RSUs from AnaptysBio vest?

The 4,000 RSUs granted to Rita Jain are scheduled to vest 100% on the date of AnaptysBio’s 2027 annual meeting of shareholders, provided she continues to serve the company through that date.

What are Rita Jain’s AnaptysBio derivative holdings after these transactions?

Following the reported transactions, Rita Jain beneficially owns 5,500 stock options and 4,000 RSUs related to AnaptysBio common stock, all reported as held directly.

Are the equity awards to AnaptysBio director Rita Jain subject to continued service conditions?

Yes. The filing states that the stock option’s monthly vesting and the RSUs’ vesting at the 2027 annual meeting are each subject to Rita Jain’s continued provision of service to AnaptysBio on each applicable vesting date.